Market potential Targeted outreach to clinical institutions and hospitals involved in radiotherapy, leveraging Celestial Oncology’s Galileo 4π technology as a disruptive upgrade from legacy systems to drive multi-institution pilot programs and 510(k) clearance partnerships.

Regulatory progress Monitor and align opportunity timing with regulatory milestones for 510(k) clearance within the next year, offering coordinated timelines and pre-clearance clinical collaboration to accelerate procurement decisions.

Strategic partnerships Position as a UCLA spinout with advanced algorithms and a compact linac as a value proposition for academic medical centers and large hospital networks seeking cutting edge radiotherapy capabilities and differentiated patient outcomes.

Proof of value Develop case studies and ROI analyses around improved beam path optimization, reduced treatment times, and potential dose accuracy gains to support budget approvals and payer discussions.

Funding and scale Leverage Series A momentum to engage strategic investors and potential OEM collaborators, while outlining global market entry plans and service/support models to reassure large-scale buyers and health systems.